Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Charles River Laboratories International Inc.
Headquarters: Wilmington, MA, United States of America
Website: http://www.criver.com
Year Founded: 1947
Status: Public
Industry Sector: CommercialServices
CEO: James C. Foster
Number Of Employees: 20,100
Enterprise Value: $12,093,120,760
PE Ratio: 650.8
Exchange/Ticker 1: NYSE:CRL
Exchange/Ticker 2: N/A
Latest Market Cap: $8,537,067,520
BioCentury | Oct 19, 2024
Finance
Biotech restructurings show signs of slowing
Temporary respite or reflection of a stabilizing sector?
BioCentury | Aug 14, 2023
Management Tracks
Gardner named CEO of Flagship’s Ampersand
Plus: Brian Powl joins Kura as CCO, and updates from BioNTech, Allogene, CG and more
BioCentury | May 5, 2023
Management Tracks
Walensky resigning as CDC director
Plus: Riva to lead Transgene as CEO and updates from Aerami, Ginkgo and Tris
BioCentury | Dec 3, 2022
Finance
Dec. 2 Quick Takes: Liminatus heads for NASDAQ via SPAC deal
Plus: FDA clears Beam’s CD7-targeting CAR T for clinical trial, and updates from GSK, Theratechnologies, PictorLabs and more
BioCentury | Apr 26, 2022
Management Tracks
Nektar to cut 70% of staff; Nuyten, Northcott to depart
Plus Carisma names co-founder Klichinsky as CSO and updates from Caravella, Reeve Foundation, Evonetix and more
BioCentury | Mar 28, 2022
Management Tracks
Asif Ali to join Protagonist as CFO
Plus new CMO at Avenge Bio, new CEO at
BioCentury | Dec 18, 2021
Deals
Dec. 17 Quick Takes: Ipsen, Genfit advancing former NASH candidate in PBC
Plus: ALS play Amylyx seeking NASDAQ listing and updates from Novartis, Pfizer-BioNTech, IN8bio and more
BioCentury | Nov 6, 2021
Deals
Nov. 5 Quick Takes: $103M raise to support bit.bio’s cell coding tech
Plus Alphabet launches digital biology venture, IO Biotech’s IPO, setbacks for Deciphera, Calithera and more
BioCentury | May 17, 2021
Deals
May 17 Quick Takes: Antengene adds CD73 inhibitor to pipeline via Calithera deal; plus Aadi, Apellis, Charles River-Vigene, FDA and Sanofi-GSK
Seven months after its $360 million IPO on the Hong Kong stock exchange, Shanghai-based Antengene Corp. Ltd. (HKEX:6996) is building out its pipeline with exclusive, worldwide development and
BioCentury | Mar 25, 2020
Product Development
CROs might be the engine that keeps preclinical research moving during COVID-19
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Items per page:
1 - 10 of 130